Ono Pharmaceutical Co., Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ON4.MU | OS1.F | OFK.F | D4S.F | REC.VI | CUP.F | |
|---|---|---|---|---|---|---|
| Market cap | 6.59B | 36.15B | 14.28B | 31.06B | 11.03B | 65.86B |
| P/E (TTM) | 16.7 | 17.2 | 21.7 | 20.3 | 22.3 | 24.0 |
| Forward P/E | — | — | — | 46.1 | — | 0.3 |
| Price/book | 1.3 | 2.0 | 10.2 | 3.1 | 5.1 | 5.6 |
| Dividend yield | 3.48% | 1.74% | 1.82% | 3.57% | 2.67% | 1.93% |
| 1-year change | +23.90% | +40.76% | +71.74% | −17.43% | +4.74% | −1.62% |
| Today | +4.39% | +2.99% | +2.99% | +5.64% | −0.28% | +4.33% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All ON4.MU news ›Ono Pharmaceutical Co., Ltd. 2027 Q2 - Results - Earnings Call Presentation
2026-11-03. The following slide deck was published by Ono Pharmaceutical Co., Ltd. The following slide deck was published by Ono Pharmaceutical Co., Ltd. in conjunction with their 2027 Q2 earnings call.
More from 1 other outlet
Ono Pharmaceutical Q2 GAAP EPS of ¥95.60, revenue of ¥232.5B
Ono Pharmaceutical Q2 earnings: EPS ¥95.60, revenue down 9.6%, but profit rose. - Ono Pharmaceutical press release (OPHLF): Q2 GAAP EPS of ¥95.60. - Operating profit for the six-month period grew 11.2% year-on-year to ¥57.91B, while core…
Head to Head Analysis: Merck KGaA (OTCMKTS:MKKGY) and Ono Pharmaceutical (OTCMKTS:OPHLF)
Posted by Defense World Staff on Oct 25th, 2026 Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) and Merck KGaA (OTCMKTS:MKKGY – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the…
Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Crosses Above Fifty Day Moving Average – Should You Sell?
Posted by Tristan Rich on Oct 18th, 2026 Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report)’s share price crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $15.09 and…
Biohaven Licenses IgG Degrader Portfolio to Ono Pharmaceutical for $80M Upfront, 20% Royalties
TradingView Biohaven Licenses IgG Degrader Portfolio to Ono Pharmaceutical for $80M Upfront, 20% Royalties Biohaven entered into a Collaboration and License Agreement with Ono Pharmaceutical to develop an
Biohaven Ltd. Enters Strategic Licensing Agreement with Ono Pharmaceutical Co., Ltd. for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven Ltd. announced that it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd., under which Ono will obtain an exclusive license to develop and... announced that it has entered into a…
Ono Pharmaceutical Co., Ltd. Enters Into Drug Discovery Partnership With Aitia, Inc
Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. Under the terms of the agreement, Aitia will utilize its REFS? technology to... Ono Pharmaceutical Co., Ltd announced…
Ono Pharmaceutical Co., Ltd. Partners with Phylo, Inc. to Embed Agentic AI with Every Discovery Scientist
Ono Pharmaceutical Co., Ltd. and Phylo, Inc. announced a collaboration that brings Biomni Lab, Phylo's agentic AI platform for biomedical research, to Ono's drug discovery scientists. Phylo's Biomni... Ono Pharmaceutical Co., Ltd announced…
Ono Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027
Ono Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects revenue of JPY 455,000 million, operating profit of... Ono Pharmaceutical Co., Ltd. Ono…
Ono Pharmaceutical Co., Ltd. Proposes Year End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 19, 2026 and Provides Dividend Forecasts for the Second Quarter of Year Ending March 31, 2027 and Fiscal Year Ending March 31, 2027
Ono Pharmaceutical Co., Ltd. at the AGM going to be held on June 18, 2026 proposed the year end dividend of JPY 40.00 per share for the fiscal year ended March 31, 2026 as compared to JPY 40.00 per... Ono Pharmaceutical Co., Ltd at the AGM…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com17
- defenseworld.net1
- seekingalpha.com1
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.